|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Red-cell distribution width (RDW) has been associated with inflammation and beta-2 microglobulin (B2M) with tumour load.
|
31782146 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In quantitative analysis, bone marrow uptake values in <sup>68</sup>Ga-Pentixafor (TBmU<sub>CXCR4</sub>, SUVmax, and SUVmean) were positively correlated with end organ damage, staging, and laboratory biomarkers related to tumor burden including serum β2-microglobulin, serum free light chain, and 24-h urine light chain (p < 0.05).
|
31776631 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemistry was performed to detect HLA A/B/C, β2M, CD8, p53, and programmed death-ligand 1 (PD-L1) in the center and invasive margin of the tumor in 395 stage II and III GCs using tissue array method.
|
31620857 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
To further characterize the B2M alterations in tumors, we analyzed B2M hotspot mutations in 2765 benign and malignant tumor tissues by Sanger sequencing and found B2M mutations in 9 (7.5%) microsatellite-unstable (MSU) colorectal cancers (CRCs) and 3 leukemias (0.6-1.3%), but not in other tumors.
|
30503610 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Beta 2-microglobulin (β<sub>2</sub>m) is a component of the major histocompatibility complex (MHC) class I molecule, which presents tumor antigens to T lymphocytes to trigger cancer cell destruction.
|
30810435 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Somatic B2M and HLA mutations in microsatellite stable tumors were associated with higher overall mutation burden and a larger fraction of HLA-binding neoantigens when compared to B2M and HLA wild type tumors.
|
31345234 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
HLA class II-positive and HLA class II-negative groups also showed a significant difference in complete remission rate (<i>P</i>=0.0421), HLA class I/β2 microglobulin expression (<i>P</i>=0.0165), and the number of programmed death-1-positive tumor infiltrating cells (<i>P</i>=0.0020).
|
30630986 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Beta-2-microglobulin is a serum marker of tumor burden in multiple myeloma (MM).
|
31762076 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Human leucocyte antigen (HLA) and β2 microglobulin (β2M) serve as key molecules in tumour immunity, and their expression is reduced frequently in tumour cells.
|
29297942 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Methods HRS cells from archival tumor biopsies were evaluated for 9p24.1 alterations by fluorescence in situ hybridization and for expression of PD ligand 1 (PD-L1) and the antigen presentation pathway components-β2-microglobulin, MHC class I, and MHC class II-by immunohistochemistry.
|
29394125 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
B2M gene sequencing was done using this DNA form HLA-I-negative tumors.
|
30145665 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We observed differences in B2M mutation status in MMR-deficient CRC by tumour subtypes, site, stage, grade, immune infiltrate and for overall survival that warrant further investigation in larger studies before B2M mutation status can be considered to have clinical utility.
|
28616688 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In contrast, when the molecular mechanism of the tumor MHC-I loss is irreversible ("hard") due to a genetic defect in the gene/s coding for MHC-I heavy chains (chromosome 6) or beta-2-microglobulin (B2M) (chromosome 15), malignant cells are unable to upregulate MHC-I, remain undetectable by cytotoxic T-cells, and continue to grow and metastasize.
|
28040849 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Reported findings of indolent presentation of MCL include: lack of B symptoms, normal serum lactic dehydrogenase (LDH) and β2-microglobulin levels (β2M), low MCL-International Prognostic Index (MIPI) score, maximum tumor diameter less than 3 cm, spleen size < 20 cm, positron emission tomography/computerized tomography with the Standard Uptake Value max <6, Ki-67 less than 30%, with some particular immunophenotype, such as CD5 and CD38 negative, markedly increased CD23 positive lymphocytes proportions, high expression of CD200, kappa light chain restriction, without C-myc, TP53 and NOTCH1/2 mutations, non-blastoid/pleomorphic histology, and no tumor growth on reevaluation every 2~3 months (followed for at least 6 months).
|
29246179 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The combination of three agents significantly enhanced the antitumor efficacy as assessed by tumor size, tumor markers in the serum (human soluble interleukin-2 receptor-α and β2-microglobulin) and survival of the MT-1 tumor-bearing mice, compared with all other treatment groups (P<0.05).
|
25118879 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Despite being relatively sensitive to natural killer (NK) cell-mediated killing due to the lack of HLA-I expression, when transplanted into NK cell-depleted immunocompetent mice, β2-microglobulin-null hESCs developed into tumors resembling those derived from control hESCs in severe combined immunodeficiency mice.
|
26285657 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Single-chain trimer (SCT) comprising antigen peptide, β2-microglobulin (β2m), and major histocompatibility complex (MHC) class I heavy chain was a particularly powerful strategy involved in the increase of the potency of DNA vaccine against tumors and infections.
|
25739076 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These values were compared with the presence of anemia, renal dysfunction, and bone lesions as myeloma related clinical manifestations and with serum beta-2 microglobulin and Durie-Salmon clinical stage as prognosticators related to tumor mass.
|
24995304 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Additionally, anti-β2-M Ab was able to prevent tumor growth in an immunocompetent spontaneous prostate cancer mouse model.
|
23874600 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The relationship of blood levels of the human leukocyte antigen-class-I-associated β-2 microglobulin (β2M), IGF-1, and its binding protein, IGFBP-3, with tumor monosomy-3 was evaluated.
|
23196330 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We demonstrated that ZAP-70 immunoreactivity correlated with Rai 0-IV (p = 0.002) and Binet A-C stages (p < 0.001), total tumor mass (TTM score) (p < 0.001), β2-microglobulin (p = 0.006), atypical lymphocytes (p < 0.001) and proliferative activity in bone marrow and peripheral blood (p = 0.014, p = 0.002, respectively) using χ(2) test and Mann-Whitney test.
|
23098292 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
B2M protein expression and tumour-infiltrating immune cells (CD3, CD16, CD163, CD20, CD4, CD45RO, CD56, CD68, CD8, FoxP3, GranzymeB, iNOS, mast cell tryptase, MUM1, PD1, TIA-1) were evaluated in a well characterised tissue microarray of 408 CRCs.
|
22859396 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Damage of a single β2m gene by LOH on chromosome 15 may be sufficient to generate a tumor cell precommitted to escape.
|
22833104 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumors with MSI-H were associated with the following: dense infiltration (CD45, P < 0.001); cytotoxic CD8-positive lymphocytes (P < 0.001); and a complete absence of HLA class I cell surface expression, due to inactivating β2-microglobulin (β2-m) mutation in 50% of cases.
|
21400022 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We assessed the suitability of six possible reference genes, beta-actin (ACTB), glyceraldehydes-3-phosphate dehydrogenase (GAPDH), hypoxanthine phosphoribosyl transferase 1 (HPRT1), beta-2-microglobulin (B2M), ribosomal subunit L29 (RPL29) and 18S ribosomal RNA (18S rRNA) in 20 normal and tumor stomach tissue pairs of stomach cancer patients and 6 stomach cancer cell lines, by RT-qPCR.
|
20507635 |
2010 |